Open Access

Claudin 10 acts as a novel biomarker for the prognosis of patients with ovarian cancer

  • Authors:
    • Zhongjun Li
    • Wenting Xuan
    • Lishan Huang
    • Niankun Chen
    • Zhiyong Hou
    • Biyan Lu
    • Chuangyu Wen
    • Suran Huang
  • View Affiliations

  • Published online on: April 21, 2020     https://doi.org/10.3892/ol.2020.11557
  • Pages: 373-381
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer (OC) is one of the most fatal gynecological malignancies in the world and confers a poor 5-year survival rate. The present study was designed to discover novel prognostic markers for patients with OC in order to estimate disease metastasis or recurrence. Based on the large cohorts of transcriptome data from multicenter sources, a comprehensive analysis was performed to explore potential prognostic markers. A total of 269 differentially expressed genes were identified, of which 32 were upregulated and 237 downregulated in OC tissues compared with the corresponding expression in normal tissues. Kaplan‑Meier analysis, log‑rank test and nomogram analysis were employed to demonstrate that low expression levels of claudin 10 (CLDN10) were associated with a less favorable disease prognosis. The most promising prognostic marker for OC was subsequently selected. Additionally, the prognostic nomogram was constructed in order to assess the 5‑year survival rate using CLDN10 expression as a prognostic marker for OC. Furthermore, gene set enrichment analysis and analysis of the tumor‑associated competing endogenous RNA network were performed to elucidate the potential biological processes associated with CLDN10 expression. The current results indicated that CLDN10 may influence OC progression via transforming growth factor‑β (TGF‑β)‑ or WNT/β‑catenin‑induced epithelial‑to‑mesenchymal transition (EMT). The associations among CLDN10, microRNA‑486‑5p, TGF‑β, WNT/β‑catenin and EMT should be further investigated in future studies.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Li, Z., Xuan, W., Huang, L., Chen, N., Hou, Z., Lu, B. ... Huang, S. (2020). Claudin 10 acts as a novel biomarker for the prognosis of patients with ovarian cancer. Oncology Letters, 20, 373-381. https://doi.org/10.3892/ol.2020.11557
MLA
Li, Z., Xuan, W., Huang, L., Chen, N., Hou, Z., Lu, B., Wen, C., Huang, S."Claudin 10 acts as a novel biomarker for the prognosis of patients with ovarian cancer". Oncology Letters 20.1 (2020): 373-381.
Chicago
Li, Z., Xuan, W., Huang, L., Chen, N., Hou, Z., Lu, B., Wen, C., Huang, S."Claudin 10 acts as a novel biomarker for the prognosis of patients with ovarian cancer". Oncology Letters 20, no. 1 (2020): 373-381. https://doi.org/10.3892/ol.2020.11557